TCM Biotech International Corp. is a biotechnology company specializing in the research, development, manufacturing, and global distribution of innovative pharmaceuticals and health products. Founded in 1998 and headquartered in New Taipei City, it is recognized as one of Taiwan’s leading biotech firms, and notably, the second to be approved by the Ministry of Economic Affairs as a "Biotechnology New Drug Company" for its R&D achievements. The company operates ISO 9001 certified R&D facilities, GDP certified warehouses, and a modern fungi fermentation plant geared toward medicinal applications.

TCM Biotech International Corp. focuses on developing therapeutic and preventive solutions for liver diseases, including hepatitis B, non-alcoholic fatty liver disease, and liver fibrosis, and has received patents for its proprietary supplements and diagnostic platforms such as LivPhcD and CatCHimera. Beyond liver disease, its portfolio covers pharmaceuticals for osteoporosis, diabetes, urinary tract infections, and antiviral treatments. The company maintains a strong position in the pharmaceuticals and biotech sector, routinely advancing its new drug pipeline and leveraging integrated medical channels and sales networks to enhance its market presence and competitive strength.